Home Featured Page 287

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Optimi Health Receives Health Canada NPN Product Licenses in Preparation for...

World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific...

Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101...

Red Light Holland Successfully Completes Sale and Import of iMicrodose Psychedelic...

PT235 – The Entheo Society of Washington – Dismantling Power Systems...

Pharmadrug Initiates DMT Research Activities via Collaboration with the University of...

Mydecine Innovations Group Provides Update on European Operations

Numinus Wellness Inc. Announces Upsized Bought Deal Public Offering to $35...

DC’s Initiative 81 Becomes Law: Effectively Decriminalizes Entheogenic Plants and Fungi

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50%...

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.